Tracked deals
24
24 tracked deals across 2020-2026.
Pharmaceuticals Buyers & Acquisitions in New Jersey
Buyer mix
Mixed buyer set
18 strategic · 13 pe
Top trend
Volume peaked in 2024
5 tracked deals announced in 2024.
Primary Insight
What Stands Out
- CDMO and drug product manufacturing capabilities recur across deals, including cGMP fill-and-finish, oral solid dosage, and sterile/parenteral services.
- Specialty pharma transactions include product and IP acquisition (e.g., Cosette’s Vyleesi acquisition) alongside ownership and growth investments.
- New Jersey shows up not only as a deal location but also as a site expansion focus (e.g., Ardena’s Somerset facility; Aptar’s Boonton capabilities; Noramco adds Whippany).
- Several deals involve private equity and partner-led platforms, including acquisitions backed or executed by firms such as GHO Capital Partners LLP and Olympus Partners.
| Theme seen in NJ | Example buyers/targets (from this page) |
|---|---|
| Drug product / formulation manufacturing | Ardena acquiring Catalent Somerset facility; Noramco acquiring Cambrex drug product unit |
| Clinical supply / trial materials | Aptar Pharma acquiring Mod3 Pharma clinical trial materials capabilities |
| Specialty product & IP | Cosette Pharmaceuticals acquiring Vyleesi |
| Platform build via services | Advent International and Warburg Pincus forming Simtra BioPharma Solutions |
Build a buyer list for your Pharmaceuticals deal
Find buyers actively acquiring pharmaceuticals companies.
Find buyers like these for your dealBuyer Snapshot
Top Buyers
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| 1315 Capital | 1 | Growth equity firm providing expansion/growth capital to ... | PE |
| ANI Pharmaceuticals, Inc. | 1 | Integrated specialty biopharmaceutical company that devel... | Strategic |
| APNAR Pharma LP | 1 | Privately owned pharmaceutical company that develops, man... | Strategic |
| Actylis | 1 | Global supplier and manufacturer of differentiated specia... | Strategic |
| Advent International | 1 | Global private equity firm focused on buyouts and growth ... | PE |
| Alfasigma S.p.A. | 1 | Italian pharmaceutical company focused on prescription me... | Strategic |
| Alora Pharmaceuticals, LLC | 1 | Specialty pharmaceuticals company that acquires, manufact... | Strategic |
| Ampersand Capital Partners | 1 | Middle-market private equity firm focused on growth-orien... | PE |
| Aptar Pharma | 1 | Global provider of drug delivery, active material science... | Strategic |
| Ardena | 1 | Contract Development and Manufacturing Organization (CDMO... | Strategic (PE-backed) |
Acquisition Volume in Pharmaceuticals in New Jersey by Year
Last 7 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
March 6, 2026
- Buyer
- Kuva Labs, Inc.
- Target
- Lisata Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
Kuva Labs, Inc. has entered into a definitive agreement to acquire Lisata Therapeutics, Inc. for $5.00 per share in cash, plus a contingent value right (CVR) that could pay an additional $1.00 per share upon an FDA-related regulatory milestone tied to certepetide. The transaction is expected to close in the second quarter of 2026, subject to customary tender offer conditions, including tender of a majority of Lisata’s outstanding shares.
-
July 15, 2025
- Buyer
- Aptar Pharma (AptarGroup, Inc.)
- Target
- Mod3 Pharma (formerly Enteris Biopharma) - clinical trial materials manufacturing capabilities
- Seller
- SWK Holdings
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Divestiture
Aptar Pharma has acquired the Phase 1 and 2 clinical trial materials manufacturing capabilities of Mod3 Pharma (formerly Enteris Biopharma) from SWK Holdings. The deal adds cGMP fill-and-finish, high-potency API suites and biologics capabilities at a Boonton, New Jersey facility to Aptar's drug delivery and early-stage development services to accelerate adoption of its delivery technologies.
-
- Buyer
- Kaken Pharmaceuticals, KAKEN INVESTMENTS INC.
- Target
- Aadi Subsidiary, Inc.
- Seller
- Aadi Bioscience, Inc., Whitehawk Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Divestiture
Whitehawk Therapeutics completed the divestiture of Aadi Subsidiary, Inc. (including the Aadi Bioscience name, trademarks, and the FYARRO (sirolimus protein-bound particles for injectable suspension) business) to Kaken Pharmaceuticals for $100 million in cash plus customary adjustments. Whitehawk plans to use proceeds (along with a $100M PIPE financing) to develop its ADC portfolio and for general corporate and working capital needs.
-
February 24, 2025
- Buyer
- Olympus Partners
- Target
- PAI Pharma
- Seller
- Enhanced Healthcare Partners, Bourne Partners Strategic Capital
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
Olympus Partners has acquired PAI Pharma, a leading U.S. developer, manufacturer and distributor of generic oral liquid medicines. The platform was previously owned by Enhanced Healthcare Partners and Bourne Partners Strategic Capital; terms were not disclosed and Monroe Capital provided senior financing for the deal.
-
October 29, 2024
- Buyer
- 1315 Capital, East Seattle Partners, Harro Höfliger Packaging Systems, Inc., Kineticos Ventures
- Target
- Experic
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Growth capital
Experic, a Cranbury, New Jersey-based CDMO and clinical trial supply services firm, received a growth capital investment led by 1315 Capital with participation from existing investors East Seattle Partners, Harro Höfliger Packaging Systems, Inc., and Kineticos Ventures. The capital will be used to enhance Experic’s manufacturing capabilities and accelerate its international expansion to better serve biopharmaceutical clients.
-
- Buyer
- Ardena, GHO Capital Partners LLP
- Target
- Catalent (Somerset, New Jersey manufacturing facility)
- Seller
- Catalent
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Addon
Ardena, a GHO Capital-backed CDMO, has signed a definitive agreement to acquire Catalent's FDA-approved drug product manufacturing facility in Somerset, New Jersey. The acquisition — expected to close in early 2025 subject to approvals — expands Ardena's US footprint and downstream capabilities in oral solid dosage manufacturing and bioanalytical services.
-
October 7, 2024
- Buyer
- Actylis
- Target
- Pharm-Rx
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
Actylis has acquired Pharm-Rx, a Saddle Brook, New Jersey-based supplier of specialty ingredients for the vitamin, mineral and supplement (VMS), OTC and pharmaceutical markets. The deal expands Actylis' nutrition and OTC capabilities and supplier partnerships; Pharm-Rx will continue to operate under its brand and Mark Bostel will become President, Global Nutrition and OTC for Actylis. Financial terms were not disclosed.
-
July 17, 2024
- Buyer
- Funds managed by Hamilton Lane
- Target
- Cosette Pharmaceuticals
- Seller
- Avista Capital Partners, Avista's co-investors
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Growth capital
Funds managed by Hamilton Lane have acquired a significant equity interest in Cosette Pharmaceuticals from Avista Capital Partners and its co-investors. Avista and Hamilton Lane will jointly control Cosette as the company strengthens its balance sheet to accelerate R&D, product innovation and future M&A activity.
-
- Buyer
- Cosette Pharmaceuticals, Inc., Avista Healthcare Partners
- Target
- Vyleesi (bremelanotide injection)
- Seller
- Palatin Technologies, Inc.
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Divestiture
Cosette Pharmaceuticals, a U.S. specialty pharmaceutical company backed by Avista Healthcare Partners, has acquired the Vyleesi (bremelanotide) product and related intellectual property from Palatin Technologies. The deal transfers five Orange Book-listed patents (protection through 2041) and aims to expand Cosette’s women's health portfolio while ensuring continued patient access during the transition.
-
- Buyer
- Noramco
- Target
- Cambrex Drug Product Business Unit (formerly Halo Pharmaceuticals)
- Seller
- Cambrex
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Divestiture
Noramco has completed the acquisition of the Cambrex Drug Product Business Unit (previously Halo Pharmaceuticals), adding drug product formulation development, clinical and commercial manufacturing, and packaging capabilities from sites in Mirabel, Québec and Whippany, New Jersey. The purchase expands Noramco's service offering beyond APIs, brings nearly 400 employees into the Noramco group, and represents Cambrex's strategic divestiture to focus on its drug substance and analytical testing businesses.
-
October 2, 2023
- Buyer
- Advent International, Warburg Pincus
- Target
- Simtra BioPharma Solutions
- Seller
- Baxter International Inc.
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Divestiture
Advent International and Warburg Pincus completed the acquisition of Baxter International's BioPharma Solutions (BPS) business for $4.25 billion in cash, creating a standalone CDMO named Simtra BioPharma Solutions. Simtra will operate manufacturing sites in Bloomington, Indiana and Halle, Germany, establish a corporate headquarters in New Jersey, and employ approximately 1,700 people to provide sterile contract manufacturing and parenteral delivery services to pharma and biotech customers.
-
September 27, 2023
- Buyer
- Azurity Pharmaceuticals, Inc.
- Target
- Slayback Pharma LLC
- Seller
- KKR, Everstone Capital
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Addon
Azurity Pharmaceuticals has completed the acquisition of Slayback Pharma LLC from existing investors including KKR and Everstone Capital, making Slayback a wholly owned subsidiary of Azurity. The deal expands Azurity's R&D and complex formulation capabilities and accelerates its pipeline for new medicine launches as part of its growth strategy under majority owner QHP Capital.
-
September 26, 2023
- Buyer
- Alfasigma S.p.A.
- Target
- Intercept Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. for $19.00 per share in cash, representing an 82% premium to Intercept’s closing price on September 25, 2023. The deal is structured as a cash tender offer followed by a second-step merger and is expected to close by the end of 2023, pending conditions including a minimum tender and regulatory requirements.
-
June 15, 2023
- Buyer
- RK Pharma Inc
- Target
- VGYAAN Pharmaceuticals LLC
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
RK Pharma Inc., a vertically integrated pharmaceutical company based in Pearl River, New York, has completed the acquisition of VGYAAN Pharmaceuticals LLC, a specialty pharmaceutical company headquartered in Skillman, New Jersey. The deal brings VGYAAN's product portfolio and experienced management team into RK Pharma's vertically integrated platform, enhancing capabilities across complex product development, APIs and finished-dosage manufacturing; terms were not disclosed.
-
October 25, 2022
- Buyer
- Symeres, Keensight Capital
- Target
- Exemplify BioPharma
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Addon
Symeres, a Netherlands-headquartered transatlantic CRO/CDMO majority‑owned by Keensight Capital, has acquired Exemplify BioPharma, a Cranbury, New Jersey-based CMC-focused CRO. The deal strengthens Symeres' capabilities in process and analytical chemistry and formulation development and further expands its strategic foothold in the United States.
-
April 13, 2022
- Buyer
- Halozyme Therapeutics, Inc.
- Target
- Antares Pharma, Inc.
- Seller
- Antares shareholders
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
Halozyme Therapeutics will acquire Antares Pharma for $5.60 per share in cash, valuing Antares at approximately $960 million. The deal, approved unanimously by both boards, is intended to expand Halozyme's drug delivery capabilities by adding Antares' auto-injector platform and commercial specialty products and is expected to be accretive to Halozyme's 2022 revenue and non-GAAP earnings.
-
February 3, 2022
- Buyer
- APNAR Pharma LP
- Target
- Aurex Laboratories
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
APNAR Pharma LP, a privately owned pharmaceutical company based in Chino, California, has acquired East Windsor, New Jersey–based Aurex Laboratories. The deal adds US FDA–approved finished dosage manufacturing capabilities to APNAR’s platform, expanding its U.S. footprint, pipeline capacity and contract manufacturing capabilities to support APNAR’s ANDAs and third‑party partners.
-
- Buyer
- H.I.G. Capital
- Target
- Rising Pharma Holdings, Casper Pharma
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Growth capital
An affiliate of H.I.G. Capital has made a strategic equity investment in Rising Pharma Holdings and Casper Pharma (together, Rising Pharmaceuticals) to support the company's growth, M&A activity and new product launches. Rising Pharmaceuticals is an asset-light developer and marketer of generic and specialty pharmaceuticals based in New Jersey with a diversified portfolio of over 125 products and a network of 23+ CMO/CDO partners.
-
August 30, 2021
- Buyer
- Alora Pharmaceuticals, LLC
- Target
- Osmotica Pharmaceutical US LLC, Vertical Pharmaceuticals, LLC, Trigen Laboratories, LLC, Marietta, Georgia manufacturing facility (Osmotica)
- Seller
- Osmotica Pharmaceuticals plc
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Divestiture
Alora Pharmaceuticals, LLC closed the acquisition of Osmotica Pharmaceuticals plc's legacy U.S. business (including Osmotica Pharmaceutical US LLC, Vertical Pharmaceuticals, LLC and Trigen Laboratories, LLC) and the Marietta, Georgia manufacturing facility on August 27, 2021. Osmotica received approximately $111 million in proceeds, which it said would be used to retire a substantial portion of outstanding debt and to focus the company on its ophthalmic product UPNEEQ.
-
- Buyer
- Aztiq Pharma Partners
- Target
- Alvogen US
- Seller
- Alvogen Lux Holdings
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Growth capital
Aztiq Pharma Partners completed a $100 million financing to acquire a newly issued 17% equity stake in Alvogen US at a pre-money valuation of $350 million, with Morgan Stanley leading the financing. The funding will support increased R&D investment and expansion of branded sales channels in the U.S., and following the transaction Aztiq holds a combined direct and indirect stake of approximately 40% in Alvogen US.
-
- Buyer
- Signet Healthcare Partners
- Target
- Ascendia Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Growth capital
Signet Healthcare Partners, a New York-based growth equity firm, has made a growth equity investment in Ascendia Pharmaceuticals, a North Brunswick, New Jersey-based specialty CDMO. The proceeds will fund Ascendia's facility expansion and increased manufacturing capacity; Signet principals James Gale and Dr. Theron Odlaug will join Ascendia's board.
-
March 9, 2021
- Buyer
- ANI Pharmaceuticals, Inc., Ampersand Capital Partners
- Target
- Novitium Pharma
- Seller
- Novitium Pharma shareholders (including founders Samy Shanmugam, Chad Gassert and Vijay Thorappadi)
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
ANI Pharmaceuticals completed the acquisition of Novitium Pharma for $163.5 million (including $89.5M cash and $74M equity, plus up to $46.5M in contingent earn-outs), adding a U.S.-based R&D engine and CDMO manufacturing capacity. The deal, financed with a new $300M Term Loan B, a $40M revolver and a $25M PIPE investment from Ampersand Capital Partners, is expected to be immediately accretive and expand ANI's generics, contract manufacturing and 505(b)(2) capabilities.
-
June 5, 2020
- Buyer
- UCB
- Target
- Engage Therapeutics
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
Belgium-based biopharma UCB has acquired Summit, New Jersey-based Engage Therapeutics for an upfront cash payment of US$125 million plus up to US$145 million in milestone payments, gaining worldwide rights to Staccato Alprazolam. The acquisition adds a late-stage, drug-device rescue therapy candidate for epilepsy to UCB's neurology portfolio and includes updated license and supply agreements with Alexza Pharmaceuticals.
-
January 28, 2020
- Buyer
- BioPharmX Corporation
- Target
- Timber Pharmaceuticals LLC
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
BioPharmX Corporation (NYSE American: BPMX) entered into a definitive merger agreement with Timber Pharmaceuticals LLC whereby a BioPharmX subsidiary will merge into Timber, leaving Timber as a wholly‑owned subsidiary of BioPharmX. The transaction will bring at least $20 million of financing to the combined company, after which BioPharmX will change its name to Timber Pharmaceuticals and Timber’s management will become the combined company's leadership.
Full Export
Purchase this data
Get the full acquisitions list for this page as CSV + XLSX.
Build a buyer list for your Pharmaceuticals deal
Find buyers actively acquiring pharmaceuticals companies.
Frequently Asked Questions
What kinds of pharmaceuticals acquisitions are covered for New Jersey?
The page focuses on acquisitions and major ownership changes across specialty pharma products, drug product manufacturing, and CDMO/clinical trial supply capabilities located in or tied to New Jersey.
Which recurring deal themes appear most often?
Manufacturing and capabilities expansions (e.g., drug product facilities, clinical trial materials manufacturing, and formulation/delivery services) appear repeatedly, alongside some product and IP transfers.
Do New Jersey transactions include both acquisitions and equity investments?
Yes. The page includes completed acquisitions as well as equity investment activity and platform-building transactions (for example, Hamilton Lane’s significant equity interest in Cosette Pharmaceuticals).
Are terms like regulatory milestones or FDA-related approvals reflected in these deals?
Often, yes. At least one transaction describes a contingent value right tied to an FDA-related regulatory milestone, and others reference FDA-approved manufacturing facilities or expected closing subject to approvals.
Related Acquisition Pages
Pharmaceuticals Buyers & Acquisitions
Pharmaceuticals Buyers & Acquisitions in Canada
Private Equity-Backed Pharmaceuticals Buyers
Pharmaceuticals Acquisitions in 2026
Pharmaceuticals Acquisitions in 2025
Pharmaceuticals Acquisitions in 2024
Pharmaceuticals Acquisitions in 2023
Pharmaceuticals Acquisitions in 2022
Pharmaceuticals Acquisitions in 2021
Acquisitions in New Jersey
Private Equity-Backed Acquisitions in New Jersey
Acquisitions in New Jersey in 2026